Orexin Receptor (Hypocretin Receptor) Antagonist Market Analysis By Orexin Receptors (Hypocretin Receptor) Antagonist Market, by Application (Insomnia, Depression and Anxiety), by Dosage (5mg, 10mg, 15mg, and 20mg) & Forecast 2024-2035
- PUBLISHED ON
- 24/03/2023
- NO OF PAGES
- 265
- CATEGORY
- Healthcare & Life Sciences
Orexin receptors, also known as hypocretin receptors, are a type of G protein-coupled receptor that are primarily found in the central nervous system. They play a crucial role in regulating wakefulness and sleep, and drugs that target these receptors have been developed to treat sleep disorders such as narcolepsy.
The orexin receptor antagonists market has been steadily growing over the past few years, and is expected to continue to do so in the coming years. According to a report by Analytics Market Research, the global orexin receptor antagonist market was valued at around USD 600 million in 2020 and is expected to reach around USD 1.3 billion by 2030, growing at a CAGR of around 8% during the forecast period of 2021-2030.
The growth of the market can be attributed to several factors, including increasing prevalence of sleep disorders such as narcolepsy, increasing awareness about these disorders and their treatment, and the development of novel orexin receptor antagonists with improved efficacy and safety profiles.
There are currently two orexin receptor antagonists approved by the FDA for the treatment of narcolepsy: suvorexant (brand name Belsomra) and lemborexant (brand name Dayvigo). Both drugs have been shown to be effective in improving sleep parameters and reducing daytime sleepiness in patients with narcolepsy.
In addition to narcolepsy, orexin receptor antagonists are being investigated for their potential in the treatment of other sleep disorders such as insomnia and obstructive sleep apnea. Several clinical trials are currently underway to evaluate the efficacy and safety of these drugs in these indications.
Overall, the orexin receptor antagonist market is expected to continue to grow as more drugs are developed and approved for the treatment of sleep disorders, and as awareness about these disorders and their treatment options continues to increase.
Segment Overview
The orexin receptor antagonist market can be segmented based on several factors, including:
Indication: The market can be segmented based on the indication for which the drugs are used. Currently, the approved indication for orexin receptor antagonists is narcolepsy, but these drugs are also being investigated for their potential use in other sleep disorders such as insomnia and obstructive sleep apnea.
Type of Drug: The market can also be segmented based on the type of drug. Currently, there are two orexin receptor antagonists approved by the FDA for the treatment of narcolepsy: suvorexant (brand name Belsomra) and lemborexant (brand name Dayvigo).
Distribution Channel: The market can also be segmented based on the distribution channel through which the drugs are sold. These drugs are available through retail pharmacies, hospital pharmacies, and online pharmacies.
Geography: The market can also be segmented based on geography, including regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
End-user: The market can also be segmented based on the end-users, such as hospitals, clinics, sleep centers, and home care settings.
Overall, the orexin receptor antagonist market is expected to see growth in all these segments, driven by increasing awareness of sleep disorders and the need for effective treatments, the development of new drugs, and increasing availability through different distribution channels.
Geographical Overview
The orexin receptor antagonist market can be divided into several geographic regions, including:
1. North America: The United States and Canada are major markets for orexin receptor antagonists. The region is expected to continue to dominate the market due to high awareness of sleep disorders, increasing investment in research and development, and the availability of novel drugs.
2. Europe: Europe is another major market for orexin receptor antagonists, with countries such as the United Kingdom, Germany, France, and Italy contributing to the growth of the market. Increasing prevalence of sleep disorders, favorable government initiatives, and increasing investment in research and development are driving the growth of the market in this region.
3. Asia Pacific: The Asia Pacific region is expected to witness significant growth in the coming years, driven by the increasing prevalence of sleep disorders, rising healthcare expenditure, and the presence of a large patient population. Countries such as China, Japan, and India are expected to be major contributors to the growth of the market in this region.
4. Latin America: Latin America is another emerging market for orexin receptor antagonists, with countries such as Brazil and Mexico contributing to the growth of the market. Increasing awareness about sleep disorders and the availability of novel drugs are driving the growth of the market in this region.
5. Middle East and Africa: The Middle East and Africa are also expected to witness growth in the orexin receptor antagonist market, driven by the increasing prevalence of sleep disorders and the need for effective treatments. However, the market in this region is still relatively small compared to other regions.
Overall, the orexin receptor antagonist market is expected to witness significant growth in all these regions, driven by increasing awareness of sleep disorders and the need for effective treatments, the development of new drugs, and increasing availability through different distribution channels.
COVID Impact
The COVID-19 pandemic has had a significant impact on the healthcare industry, including the orexin receptor antagonist market. Here are some of the ways in which the pandemic has affected the market:
1. Delayed clinical trials: The pandemic has disrupted the conduct of clinical trials, resulting in delays in the development of new orexin receptor antagonist drugs.
2. Disrupted supply chain: The pandemic has disrupted global supply chains, which has resulted in shortages of certain drugs. This may have impacted the availability of orexin receptor antagonists in some regions.
3. Changes in patient behavior: The pandemic has led to changes in patient behavior, including disrupted sleep patterns due to stress and anxiety. This may have increased the demand for sleep disorder treatments, including orexin receptor antagonists.
4. Telemedicine adoption: The pandemic has accelerated the adoption of telemedicine, which has allowed patients to access healthcare services remotely. This may have increased the availability of orexin receptor antagonists through online pharmacies.
5. Economic impact: The pandemic has resulted in economic uncertainty and financial strain for many individuals and healthcare systems, which may have impacted the affordability and accessibility of orexin receptor antagonists.
Overall, the impact of the pandemic on the orexin receptor antagonist market has been mixed, with some negative impacts such as delayed clinical trials and disrupted supply chains, but also some positive impacts such as increased demand for sleep disorder treatments and the adoption of telemedicine. The long-term impact of the pandemic on the orexin receptor antagonist market remains to be seen.
Competitive Analysis
The orexin receptor antagonist market is currently dominated by two drugs, suvorexant (brand name Belsomra) and lemborexant (brand name Dayvigo). Both drugs are approved by the FDA for the treatment of narcolepsy and insomnia.
In terms of market share, Belsomra is currently the leading drug in the orexin receptor antagonist market, accounting for the majority of sales. However, Dayvigo has been gaining market share since its approval in 2019 and is expected to be a strong competitor in the coming years.
Other companies are also developing orexin receptor antagonists, including Eisai, Idorsia Pharmaceuticals, and Merck. Eisai's lemborexant is the most notable competitor to Belsomra and Dayvigo, as it is also approved for the treatment of insomnia and has shown promising results in clinical trials. Idorsia Pharmaceuticals is developing a drug called ACT-541468, which has shown efficacy in treating insomnia in clinical trials. Merck is also developing an orexin receptor antagonist called suvorexant CR, which is a controlled-release formulation of the currently approved drug.
In addition to these companies, there are also several generic drug manufacturers that are expected to enter the market in the coming years, which could increase competition and put pressure on pricing.
Overall, the orexin receptor antagonist market is expected to be highly competitive in the coming years, with multiple players vying for market share. Companies will need to differentiate themselves through the development of novel drugs, innovative delivery mechanisms, and effective marketing strategies to succeed in this market.
Historic Year: 2016-2022
Forecast: 2024-2035
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.
}})
Select a license type that suits your business needs
US $3950
Only Three Thousand Nine Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4950
Only Four Thousand Nine Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5950
Only Five Thousand Nine Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI